Clinical trials: Motor Fluctuations
Idiopathic Parkinson's Disease
Randomized Safety Study of CVT-301 Compared to an Observational Control Group
This study is a 12-month, open-label, randomized, multicenter study which will evaluate the safety and efficacy of CVT-301 for the treatment of up to 5 OFF episodes per day in Parkinson's Disease (PD) patients experiencing motor…
- Trial name
- NCT02352363
- Testing
- CVT-301, Observational cohort
- Where
- 76 sites in United States, Austria and 12 more
- Volunteers
- 408 people
- Sponsor
- Acorda Therapeutics
Parkinson's Disease, Motor Fluctuations
Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations
The primary objective of this study is to explore the efficacy and tolerability of DM-1992 compared to a standard carbidopa/Levodopa Immediate-Release (CD/LD IR) tablet (Sinemet IR) as measured by: "ON" time with no dyskinesia or…
- Trial name
- NCT01515410
- Testing
- DM-1992, Sinemet IR
- Where
- 7 sites in United States
- Volunteers
- 34 people
- Sponsor
- Depomed
Parkinson's Disease
A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations
This is a randomized, double-blind, two treatment, two group, parallel group study. Subjects will be randomized to one of two treatment groups (E2007 or Placebo) in a 3 to 1 ratio and receive treatment for a total of ten weeks…
- Trial name
- NCT00165789
- Testing
- E2007
- Where
- 10 sites in United States
- Volunteers
- 75 people
- Sponsor
- Eisai Inc.
Advanced Parkinson's Disease
Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction
The primary purpose is to demonstrate superiority of Rotigotine over Placebo on motor symptoms when used in subjects with symptoms of Gastrointestinal Dysfunction. Hypothesis: Rotigotine will decrease OFF time compared to Placebo.
- Trial name
- ROADMAP (NCT01536015)
- Testing
- Rotigotine
- Where
- 26 sites in United States
- Volunteers
- 25 people
- Sponsor
- UCB Pharma
Parkinson's Disease
Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies
An extension study for participants who have completed a prior VY-AADC01 clinical study
- Trial name
- NCT03733496
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Neurocrine Biosciences
Parkinson Disease (PD)
Sensor-Based Optimization of Therapy for Parkinson's Disease Patients With Motor Fluctuations
Although numerous tools have been developed in recent years with the enhancement of new technologies precision and the reduction of their size, still few medical devices are used in clinical routine in Parkinson's Disease.
- Trial name
- SO-TOP (NCT07074119)
- Testing
- wearable-based adjustment therapy
- Where
- France
- Volunteers
- 218 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Parkinson Disease
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations.
- Trial name
- NCT06553027
- Testing
- CVN424 75 mg, CVN424 150 mg
- Where
- 94 sites in United States, Australia and 7 more
- Volunteers
- 330 people
- Sponsor
- Cerevance
Parkinson's Disease
The Effect Of E2007 On Pharmacodynamic Responses To Levodopa Among Patients With Parkinson's Disease Who Experience Dyskinesia And Motor Fluctuations
A randomized, double blind, placebo-controlled study employing a mixed parallel group and fixed sequence cross-over design. Patients will be randomized to one of two treatment groups ('E2007' or 'Placebo') in a 1:1 ratio and…
- Trial name
- NCT00451633
- Testing
- E2007
- Where
- 5 sites in Germany, Italy
- Sponsor
- Eisai Inc.
Parkinson Disease
Validation of a Diagnostic Self-assessment Scale Non-motor Fluctuations at the Parkinson's Patient
The objective of this study is to validate a diagnostic tool severity of these common non-motor manifestations, disturbing and little recognized as a self-questionnaire.
- Trial name
- NCT02859805
- Testing
- validation of a diagnostic tool severity of non-motor symptoms in Parkinson patients
- Volunteers
- 255 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Parkinson´s Disease
Clinical Trial of Rasagiline in Levodopa-Treated Parkinson's Disease Patients With Motor Fluctuations
The objective of this study is to evaluate the efficacy, tolerability, and safety of rasagiline compared to placebo in PD patients with motor fluctuations on levodopa therapy.
- Trial name
- NCT01736891
- Testing
- Rasagiline
- Where
- 8 sites in China
- Volunteers
- 268 people
- Sponsor
- Chongqing Fortune Pharmaceutical Co., Ltd.
Advanced Stage Parkinson's Disease
A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia.
This is a multicenter, randomized, double blind, pramipexole-controlled parallel group study of pardoprunox as adjunctive treatment to levodopa.
- Trial name
- NCT00903838
- Testing
- pardoprunox, pramipexole
- Where
- 9 sites in Germany, Italy and 1 more
- Volunteers
- 37 people
- Sponsor
- Abbott Products
Idiopathic Parkinson's Disease
Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients
Phase 3, international, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 3-arm safety and efficacy study (Part A) with an open-label phase (Part B).
- Trial name
- TOZ-PD (NCT02453386)
- Testing
- tozadenant
- Where
- 71 sites in United States, Austria and 5 more
- Volunteers
- 449 people
- Sponsor
- Biotie Therapies Inc.
Parkinson's Disease
The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
Patients will be randomised to receive either placebo or the study drug for a period of 30 weeks, in addition to their standard Parkinsonian medications.
- Trial name
- NCT00286897
- Testing
- E2007
- Where
- 118 sites in Austria, Belgium and 15 more
- Volunteers
- 702 people
- Sponsor
- Eisai Limited
Parkinson Disease (PD), Parkinson's Disease
Real-world Patient Experiences With Inbrija®
Parkinson's disease can cause OFF episodes, when medication effects wear off and symptoms return, affecting movement, daily activities, comfort, and wellbeing.
- Conditions
- Parkinson Disease (PD), Parkinson's Disease, Off Episodes of Parkinson Disease
- Trial name
- INHALE-PD (NCT07797790)
- Testing
- Levodopa inhalation powder
- Where
- 2 sites in Austria
- Volunteers
- 120 people
- Sponsor
- Merz Therapeutics GmbH
Idiopathic Parkinson's Disease
Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
This study is a 12-month, dose-level blinded, multicenter study of 2 inhaled dose levels of CVT-301 for the treatment of up to 5 OFF episodes per day in PD patients experiencing motor fluctuations (OFF episodes).
- Trial name
- NCT02242487
- Testing
- CVT-301
- Where
- 74 sites in United States, Canada and 3 more
- Volunteers
- 325 people
- Sponsor
- Acorda Therapeutics
Advanced Stage Parkinson's Disease
An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.
This study is a multicenter, 9 months, open label extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.002 study.
- Trial name
- NCT00407095
- Testing
- Pardoprunox
- Where
- 87 sites in United States, Albania and 11 more
- Volunteers
- 140 people
- Sponsor
- Solvay Pharmaceuticals
Parkinson's Disease
A Safety, Tolerability and Pharmacokinetic Study of ND0611 on the Top of Different Oral Dosage Forms of Levodopa/Carbidopa in Parkinson's Disease Patients
A cross-over study, where ND0611 or placebo will be tested on top of 3 different LD/CD dosage forms. Safety and tolerability, pharmacokinetic profile of levodopa and carbidopa and the potential clinical effect of ND0611 will be…
- Trial name
- NCT01229332
- Testing
- Saline, Carbidopa
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- NeuroDerm Ltd.
PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease
SAD Study in Patients With Parkinson's Disease and Motor Fluctuations
This is a randomized, placebo-controlled, single ascending dose (SAD) study of SER-252 in participants with Parkinson's Disease (PD) and motor fluctuations.
- Trial name
- NCT07422675
- Testing
- SER-252 (PEOZ-apomorphine), enFuse
- Where
- 6 sites in United States, Australia
- Volunteers
- 40 people
- Sponsor
- Serina Therapeutics
Parkinson's Disease, Levodopa
Erythromycin in Parkinson's Disease
Gastroparesis (slow stomach emptying) is a common feature of Parkinson's Disease. Levodopa (Sinemet), a common medication for Parkinson's Disease, can make gastroparesis worse.
- Trial name
- NCT02005029
- Testing
- Erythromycin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Virginia Commonwealth University
Parkinson's Disease
A Safety, Tolerability and Levodopa Pharmacokinetics Study of Repeated ND0612 in Parkinson's Disease Patients
This is a randomized, placebo-controlled, double-blind, 2-period study evaluating the safety and pharmacokinetics (PK) of ND0612 in Parkinson's disease (PD) patients on an optimized oral levodopa (LD) regimen and experiencing ≥2…
- Trial name
- ND0612/003 (NCT01883505)
- Testing
- ND0612, Entacapone
- Where
- 3 sites in Israel
- Volunteers
- 30 people
- Sponsor
- NeuroDerm Ltd.